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An overall aim of treatment in multiple sclerosis is to lower the negative impact of the disease on functioning and quality of 
life of patients. Therefore, a measurement of functioning and quality of life should be included in the evaluation of the effectiveness of 
treatment. The most commonly used quality of life questionnaires, either generic or specific, were presented in this paper,. 
Information about clinical and functional status is useful in the interpretation of the quality of life assessment results. Because of that, 
instruments for the assessment of depression, cognitive functions, functional ability and fatigue in multiple sclerosis were also 
described.    
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Quality of Life in MS patients
Quality of Life (QoL) is a multi-dimensional 
construct which consists of at least three broad domains: 
physical, mental and social. In the field of medicine 
researchers and physicians have often used health-
related quality of life concept which specifically focuses on 
the impact of an illness and/or treatment on patients’ 
perception of their status of health and on subjective well-
being or satisfaction with life (Jaracz 2003)[1]. We have 
described the Quality of Life of post-stroke patients and 
their caregivers in our first report (JMed&Life 
2010;3(3):216-220)[2]. The Quality of Life of patients with 
Multiple Sclerosis is being described in this next review 
report. 
MS can cause a variety of symptoms, including 
changes in sensation, visual problems, muscle weakness, 
depression, difficulties in coordination and speech, severe 
fatigue, cognitive impairment, problems with balance, 
overheating, and pain. MS will cause impaired mobility 
and disability in more severe cases. Multiple sclerosis 
may take several different forms, with new symptoms 
either occurring in discrete attacks or slowly accruing over 
time. Between attacks, symptoms may resolve 
completely, but permanent neurologic problems often 
persist, especially as the disease advances. Currently, 
MS does not have a cure, though several treatments are 
available, that may slow the appearance of new 
symptoms. 
MS primarily affects adults, with an age of onset 
typically between 20 and 40 years old, and is more 
common in women than in men. The course of MS is 
difficult to predict, and the disease may, at times, either lie 
dormant or progress steadily. Several subtypes or 
patterns of progression, have been described. Subtypes 
use the past course of the disease in an attempt to predict 
the future course. Subtypes are important not only for 
prognosis but also for therapeutic decisions.  
Individuals with progressive subtypes of MS, 
particularly the primary progressive subtype, have a more 
rapid decline in function. In the primary progressive 
subtype, supportive equipment (such as a wheelchair or 
standing frame) is often needed after six to seven years. 
However, when the initial disease course is the relapsing-
remitting subtype, the average time until such equipment 
is needed is twenty years. This means that many 
individuals with MS will never need a wheelchair. There is 
also a more cognitive impairment in the progressive forms 
than in the relapsing-remitting MS.  
The earlier in life MS occurs, the slower disability 
progresses. Individuals who are older than fifty when 
diagnosed are more likely to experience a chronic 
progressive course, with a more rapid progression of 
disability. Those diagnosed before the age of 35 years old 
have the best prognosis. Females generally have a better 
prognosis than males. However, their Patient-Reported Journal of Medicine and Life Vol. 3, No. 4, October‐December 2010 
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Outcome (shortly PRO) is lower than in men. Women fall 
in depression and feel fatigue more often; they also suffer 
from bladder dysfunction more often. A common but often 
overlooked symptom in MS is sexual dysfunction – in 
women anorgasmia. Also stressful life events can have 
strong impact on clinical relapses in women with MS. 
These are many problems when considering motherhood, 
referring to pregnancy, child-birth and puerperium 
(especially breastfeeding) in MS. 
QoL measures are suitable as well for an 
outcome measure of a new treatment such as 
rehabilitation [3-9]. Subjective factors in QoL in MS 
patients include perception of symptoms, level of fitness, 
self-image, satisfaction with family life, work, the 
economic situation, the interaction with other people, 
social support and life in general. To the objective factors, 
we should include the clinical picture of disease, social 
status, social and living conditions and the number and 
intensity of social contacts. The scales used to assess the 
QoL in MS include either subjective or objective 
indicators, or both [3, 10]. The questionnaire may be 
completed by the patient in person or by telephone 
interview, by family members or close persons, by the 
professional carers and health professionals. The most 
desirable and reliable is the assessment by the patient 
himself, especially when the subjects of measurement are 
subjective aspects of QoL. QoL scales for patients with 
MS could be divided into universal (general - generic) and 
specific for the disease (disease - oriented).  
 
Generic questionnaires 
  Among the generic questionnaires used in 
other disease entities, the assessment of QoL in patients 
with MS mostly used are: Medical Outcome Study 36-Item 
Short Form Health Survey - SF - 36, EuroQol EQ-5D, 
Sickness Impact Profile (SIP) [9-12], Life Satisfaction 
Questionaire - LSQ) [13], WHOQOL BREF and Quality of 
Well-Being Scale - QWBS [11-17]. 
               The above-mentioned questionnaires have been 
tested in many countries. In the literature, there are 
numerous and detailed data on their validity and reliability 
- also in relation to MS [18]. The scale of the SF-36 allows 
the assessment of the eighth areas of QoL during the four 
weeks preceding the survey, it takes about 9 min to be 
filled in. It is particularly useful in predicting the course of 
the disease [19]. The disadvantages include the effect of 
the lower and upper limit and a relatively low sensitivity to 
change QoL. 
The EQ-5D scale allows the assessment of the 
fifth areas of health and self-esteem at the time of the 
study. Filling time is of 3 min. Because of the three levels 
evaluation, the EQ-5D system is poorly sensitive to QoL 
changes, especially in patients with a score of 5 and over 
by EDSS. It is primarily intended for managing healthcare 
- healthcare decision-makers [12]. 
SIP questionnaire allows the assessment of 12 
areas of functioning at the time of study and (in contrast to 
SF-36 and EQ-5D) it is sensitive to the patient`s change. 
The disadvantages of SIP include its length (136 items) 
which means that the filling time can be up to 30 minutes 
[13]. LSQ is used to assess the overall satisfaction and 
satisfaction with the eighth areas of life. The answers to 
the sixth estimated point scale from very dissatisfied to 
very satisfied [14]. QWB allows the assessment of 
mobility, physical activity, social activity and 27 
symptoms. The combination of the above categories can 
identify 43 functional levels of the patient. It is 
recommended that the questionnaire is completed by 
interview, by a person trained for that purpose. Filling time 
is between 10 - 15 min [17].  
 
Questionnaires specific for MS  
One of the most commonly used scales specific 
to MS is the Multiple Sclerosis Quality of Life Instrument 
(MSQoL-54) by Barbara Vickrey and colleagues, from the 
University of California, in Los Angeles [20, 21]. This 
scale is a modification of the SF-36, to which 18 questions 
specific to MS were added. The tool consists of 52 items 
grouped in 12 sub-scales and two distinct questions. 
These are the impact of the disease, the overall 
satisfaction with the quality of life, cognitive function, 
energy, pain, sexual function and social situation. Scale is 
protected by copyright and its application requires the 
authors’ permission each time. Another frequently used 
tool is the Functional Assessment of Multiple Sclerosis 
(FAMS), published in 1996 by David Cella and 
colleagues, from Chicago [22]. The original scale consists 
of 88 questions, was diminutive 44th positional, organized 
into six subscales. These are mobility, symptoms and 
emotional condition, satisfaction, mental activity and 
fatigue, and family welfare and social-household. In 
response to each question, the respondent has to choose 
one of five abilities to assess the degree of satisfaction. 
The Hamburg Quality of Life Questionnaire in MS – 
HAQUAMS has been published in 2001 by German 
authors [23]. It contains 38 questions organized into five 
domains: mobility of upper limbs, lower limb mobility, 
social functioning, mood and fatigue / thinking. 
HAQUAMS largely is based on the SF - 36 and FAMS.   
             The tool referring only to the subjective indicators 
of QoL in MS is Quality of Life Index - QLI, published in 
1984 by Carol Ferrans and Marjorie Powers from the 
University of Illinois in Chicago. There is a generic version 
of the tool, and six specific varieties, including patients 
with MS [24]. The Questionnaire on QoL in MS patients, 
like other versions, consists of two parts containing 35 
questions each. In the first part of the test, answers are 
given to the questions regarding the satisfaction or 
dissatisfaction of people on various aspects of their lives. 
In the second part, answers are given to questions 
regarding the importance of these spheres of life to the 
person. The answer to the sixth point scale estimate. The 
final evaluation for the total scale and four subscales 
represents the importance of scoring from both parts. Due Journal of Medicine and Life Vol. 3, No. 4, October‐December 2010 
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to the length and method to record responses, a very 
good cooperation is required from the patient.   
              In  addition to those mentioned above for the 
evaluation of QoL in patients with MS, the following are 
also applied: the Multiple Sclerosis Impact Scale - MSIS-
29 [25, 26] and Multiple Sclerosis Quality of Life Inventory 
- MSQLI. The MSIS-29 is based on self-assessment 
results of treatment for physical and mental health [27, 
28]. MSQLI contains 138 items, organized into 10 generic 
and specific subscales [29, 30].  
 
Evaluation of cognitive functions and depression 
              Scores of QoL are usually supplemented by a 
study of cognitive function and depression, since these 
factors significantly affect the sense of quality of life, as 
well as an important context for the interpretation of test 
results JŻ. Severe cognitive impairment and depressive 
symptoms may be a contraindication to test PRO. Scoring 
QoL in patients with MS, especially when it is done for 
scientific purposes, requires the measurement of the 
functional status and fatigue, because in addition to 
depression and cognitive impairment, they are the most 
important determinants of QoL in patients with MS. 
Following, a review of the most commonly used 
questionnaires to assess the emotional and cognitive 
functions is made.  
According to different authors, cognitive 
dysfunctions are observed in 40 - 65% of patients with 
MS. In preliminary diagnosis of these disorders, the most 
often used tests are: the Benton test, Mini Mental State 
Examination (MMS), Clock Drawing Test, Rosenbaum 
vision screening test (Pocket Vision Screener - PVS), 
Wechsler test [2, 25, 31-37]. 
              The specific neuropsychological tests commonly 
used are: Controlled Oral Word Association Test 
(COWAT), California Verbal Learning Test (CVLT), Digit 
Symbol Modality Task (SDMT), Delis-Kaplan Executive 
Function System (D-KEFS), Paced Auditory Serial 
Addition (PASAT) [32, 33, 37-39]. The negative impact of 
cognitive impairment on QoL was demonstrated in a 
number of studies. Among others in the work of Benito - 
Leon et al, who used the Mini-Mental scale and the clock 
drawing test. The results of these tests were negatively 
correlated with 6 domains of QoL in FAMS [40]. Rivera-
Navarro et al evaluated the experiences of caregivers and 
people with MS. They concluded that social stigma, the 
lack of work and coming to terms with MS were the 
greatest issues for the patient, while support from the 
family network, the relationship that should be established 
with the patient, the impact of MS on children and the role 
played by remunerated work were the main dimensions of 
the disease for the caregiver [41]. 
               Depression in MS is fairly well understood, its 
prevalence is estimated in 15 to 60% of patients. For the 
evaluation of depression in MS, the most frequently 
applied methods are Beck's Inventory, the Hamilton scale, 
Hospital Anxiety and Depression Scale (Hospital Anxiety 
and Depression Scale - HADS), Zung scale and the 
Montgomery-Asberg scale (Montgomery-Asberg 
Depression Rating Scale - MADRS [31, 42, 43]. 
Hamilton's scale is more useful for the study of 
depression in the elderly, while Beck's scale is often used 
in younger people; previously conducted studies clearly 
indicate the negative effect of depression on QoL 
patients. In Benedict et al. studies, MS patients reported 
lower HQOL (p<0.001) and were more likely to be 
disabled (45% of patients vs. 0 controls). Physical HQOL 
was predicted by fatigue, depression, and physical 
disability. Mental HQOL was associated with only 
depression and fatigue [43]. Lobentanz et al assessed 
factors influencing QoL in MS. The results showed that 
most patients were severely disabled; almost half were 
mildly to severely depressed, suffering from reduced 
sleep quality and/or fatigue. The multiple sclerosis 
patients had more significantly lower QLI scores than 
healthy controls. EDSS and SDS (Self-rating Depression 
Scale) scores were found to be predictors of global QLI 
score. Regarding the different QLI domains, mean SDS 
scores remained predictive for all QLI items, while mean 
EDSS, PSQI (Pittsburgh Sleep Quality Index) and FSS 
(Fatigue Severity Scale) scores were only predictive for 
physical domains. In conclusion, their study clearly 
demonstrated that depressive mood is the main factor 
influencing QOL. The disability status, fatigue and 
reduced sleep quality have an impact mainly on physical 
domains of life quality [44]. 
              In  Amato  et  al  studies,  there  was  a  moderate 
inverse relationship between disability level and the 
MSQOL-54 physical composite score, and a moderate to 
strong inverse correlation between depression or fatigue 
severity and both the physical and mental composite 
scores. In a stepwise linear regression analysis, 
depression, fatigue and disability level were confirmed to 
be significant and independent predictors of quality of life 
[31].                                
              In  the  study of quality of life, self-esteem is 
sometimes extended to pain in many cases. For this 
purpose the most frequently used are: visual analogue 
pain scale (Visual Analogue Scale - VAS) and the EQ-5D 
VAS incorporated into EuroQuol 5D [12, 45, 46].  
Global fatigue 
Fatigue is one of the most common symptoms of 
multiple sclerosis and it is associated with reduced quality 
of life. It has been recently reported in the literature that 
fatigue in MS has an increasing frequency. This can be 
defined as uncontrollable apathy, lack of energy or feeling 
exhausted with no link to depression, or muscle weakness 
[44, 47-57]. In two thirds of patients with MS, it appears as 
one of the three main symptoms, and the patients' 
opinions of the most troublesome symptoms of the 
disease. Recent studies have confirmed the American 
and German studies, which underline the independence 
of the degree of fatigue, depression and physical Journal of Medicine and Life Vol. 3, No. 4, October‐December 2010 
  355 
© 2010, Carol Davila University Foundation
disability. [51, 52].  The fatigue syndrome in patients with 
MS cannot be evaluated objectively. 
That is why for the evaluation of fatigue more 
than 30 scales have been developed.  
The most frequently used are the Fatigue 
Severity Scale – FSS by Krupp et al and the Modified 
Fatigue Impact Scale (Modified Fatigue Impact Scale - 
MFIS). FSS is composed of nine items, to which the 
patient responded up to a 7-point scale estimation. The 
final result is the arithmetic mean of the scores of all 
items. The average score of FSS for patients with MS is 
6.5 [54]. MFIS is a modification of the scale Fatigue 
Impact Scale by Fisk et al. It contains 21 items, 
concerning the impact of fatigue on mental, physical and 
social functioning. The final result is the sum of points 
from the scale of individual items [50]. 
Evaluation of functional state 
  Many authors confirmed the importance of the 
evaluation of the functional status in QoL of MS, although 
it is smaller than the emotional disturbances. The most 
common measurements of functional status in patients 
with MS are the following scales: Expanded or Extended 
Disability Status Scale - EDSS by Kurtzke, The Scripps 
Neurologic Rating Scale - SNRS, Barthel Index (BI) and 
Functional Independence Measure - FIM [22, 58-60]. In 
EDSS, the precise steps are denoted by functional 
scores, which are graded from normal (0) to maximal 
impairment (5 or 6) for pyramidal, cerebellar, brain stem, 
sensory, bowel and bladder, visual, cerebral or mental, 
and other functions. Hobart et al. provided, in 2000, a 
more detailed examination by using the psychometric 
methods of Kurtzke`s EDSS and FS. Results indicated 
that the FS measure constructs distinct from each other 
(intercorrelations = -0.23 to +0. 52) and from the EDSS 
(correlations = -0.10 to +0.59). Intra-rater, but not inter-
rater reproducibility is adequate for group comparison 
studies. The FS does not satisfy criteria such as an eight-, 
seven- or six-item summed rating scale [61]. 
  In 1999, Cutter et al developed The Multiple 
Sclerosis Functional Composite – MSFC. The MSFC 
comprises quantitative functional measures of three key 
clinical dimensions of MS: leg function/ambulation, 
arm/hand function, and cognitive function. Scores on 
component measures are converted to standard scores 
(z-scores), which are averaged to form a single MSFC 
score. The time needed to fulfill all the MSFC tests is of 
about 20 min. MSFC components should be administered 
in the following order: 1. Trial 1, Timed 25-Foot Walk 
(about 7,62 m), 2. Trial 2, Timed 25-Foot Walk, 3. Trial 1, 
Dominant Hand, Nine Hole Peg Test (9-HPT), 4. Trial 2, 
Dominant Hand, 9-HPT, 5. Trial 1, Non-Dominant Hand, 
9-HPT, 6. Trial 2, Non-Dominant Hand, 9-HPT, 7. Paced 
Auditory Serial Addition Test (PASAT) [62]. 
In 9-HPT, the patients are asked to pick up nine 
pegs into nine holes while time is measured [63, 64]. In 
1977, Gronwall introduced the Paced Auditory Serial 
Addition Test (PASAT) as a measure of the severity of 
closed head injuries as well as a scale of recovery 
following a traumatic brain injury [65]. Stimulus 
presentation rates were adapted for the use with MS 
patients, by Rao and colleagues in 1989 [66], and the 
measure has been widely used in MS studies during the 
last decade. The PASAT is a measure of cognitive 
function that specifically assesses auditory information 
processing speed and flexibility, as well as calculation 
ability. PASAT is presented on an audiocassette tape or 
compact disk to control the rate of stimulus presentation. 
Single digits are presented either every 3. (3. PASAT) or 
every 2. (2. PASAT) and the patient must add each new 
digit to the one immediately prior to it. The test result is 
the number of correct sums given (out of 60 possible).  
  In Ruddick et al. report, MSFC scores in patients 
with relapsing-remitting MS predicted the level of disability 
and extended the brain atrophy from 6, to 8 years later. 
They concluded that MSFC scores may prove useful to 
assign prognosis, monitor patients during early stages of 
MS, and assess treatment effects. [67]. In Kragt et al. 
study, on over a period of 2 years in primary progressive 
multiple sclerosis, the Multiple Sclerosis Functional 
Composite (MSFC) was less responsive than the 
Expanded Disability Status Scale (EDSS). The predictive 
value of neither EDSS nor MSFC was very powerful [68]. 
Quality of Life in visual disturbances in 
Multiple Sclerosis 
  In Multiple Sclerosis, the visual pathway often 
tends to be impaired. A very early symptom, which 
precedes neurological signs, is the retrobulbar optic 
neuritis. In MS patients, near vision, such as distance, 
color and peripheral vision can be disturbed. Many 
patients are not aware of the visual impairment which 
could cause the delay in diagnose. The assessment of the 
visual field in patients with MS enables the early 
diagnosing as well as the monitoring of the course of 
disease.  
  The most important stage in monitoring the 
course of disease is the evaluation of quality of life. The 
assessment of quality of life in MS is well known, even 
better than in other neurological diseases. Less known is 
the question of quality of life, diminished because of visual 
field defects in MS. The contemporary possibility of 
evaluation of quality of life in MS patients includes the 
VFQ-25 questionnaire as a sensitive and useful tool in 
self-assessing visual function in MS patients. The VFQ-25 
consists of 25 questions comprising the 12 sub-scales. 
They concern the general feeling of health, an overall 
assessment of vision, ocular pain, near vision, distance 
vision, social functioning, mental health, difficulty in Journal of Medicine and Life Vol. 3, No. 4, October‐December 2010 
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performing the current role, autonomy, driving, color 
vision and peripheral vision [69-71]. 
Role of comorbidity in MS 
In Horton et al study the agreement between 
self-report and medical records on comorbidity in MS was 
high (kappa >0.82) for diabetes and hypertension; 
substantial (kappa = 0.62-0.80) for hyperlipidemia, thyroid 
disease, glaucoma, and lung disease; moderate (kappa = 
0.43-0.56) for osteoporosis, irritable bowel syndrome, 
migraine, depression, heart disease, and anxiety 
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